Loading...
Please wait, while we are loading the content...
Similar Documents
Update on first-line treatment of advanced ovarian carcinoma
| Content Provider | Semantic Scholar |
|---|---|
| Author | Kemp, Zachary T. Ledermann, J. A. |
| Copyright Year | 2013 |
| Abstract | Despite the high response rate to first-line treatment of advanced ovarian cancer, the vast majority of patients relapse. Maximal debulking surgery and chemotherapy with a platinum doublet have remained the standard of care for many years and new approaches are imperative. Recent clinical trials have given grounds for hope. Neoadjuvant chemotherapy, intraperitoneal delivery, and dose-dense strategies have all shown promising results, as has the targeting of angiogenesis. A greater understanding of the molecular landscape of ovarian cancer is helping to identify new treatment options. In this review, we will highlight the key trials and recent progress in these areas. |
| Starting Page | 45 |
| Ending Page | 51 |
| Page Count | 7 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://www.dovepress.com/getfile.php?fileID=15050 |
| Alternate Webpage(s) | http://ftp.ncbi.nlm.nih.gov/pub/pmc/cd/ec/ijwh-5-045.PMC3558307.pdf |
| PubMed reference number | 23378788 |
| Alternate Webpage(s) | https://doi.org/10.2147/IJWH.S30231 |
| DOI | 10.2147/ijwh.s30231 |
| Journal | International journal of women's health |
| Volume Number | 5 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Biological Markers Conflict (Psychology) Epithelial ovarian cancer Malignant neoplasm of ovary Neoadjuvant Therapy Neoplasms Patients Platinum Tumor Debulking cellular targeting ovarian neoplasm |
| Content Type | Text |
| Resource Type | Article |
